glp-1 receptor agonists and cancer risk in adults with obesity show anti-cancer benefits beyond weight loss GLP-1 receptor agonists are increasingly

Among them, gastrointestinal adverse reactions mainly occurred in the early stage of the first drug use, with mild to moderate degrees (109)

doi: 10.1093/brain/awad003

Role of GLP-1 in obesity GLP-1 reduces appetite and food intake through its actions in the CNS

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

We need to wait and see on that long-term data. Shafipour noted that tablet forms of GLP-1 medications could help people stick to weight loss routines